1-4 of 4
Esther S. Trueblood
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity

Ryan A. Heiser, Anthony T. Cao, Weiping Zeng, Michelle Ulrich, Patrick Younan, Martha E. Anderson, Esther S. Trueblood, Mechthild Jonas, Robert Thurman, Che-Leung Law, Shyra J. Gardai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 68–83.
https://doi.org/10.1158/1535-7163.MCT-23-0118
Published: 03 January 2024
View article titled, Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Open the PDF for Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications

Robert P. Lyon, Mechthild Jonas, Christopher Frantz, Esther S. Trueblood, Roma Yumul, Lori Westendorf, Christopher J. Hale, Jackie L. Stilwell, Narayana Yeddula, Katie M. Snead, Vineet Kumar, Gabriela I. Patilea-Vrana, Kerry Klussman, Maureen C. Ryan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1444–1453.
https://doi.org/10.1158/1535-7163.MCT-22-0817
Published: 01 December 2023
View article titled, SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Open the PDF for SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications in another window
Includes: Supplementary data
Journal Articles

Development of Novel Antibody–Camptothecin Conjugates

Ryan D. Lyski, Lauren B. Bou, Uland Y. Lau, David W. Meyer, Julia H. Cochran, Nicole M. Okeley, Kim K. Emmerton, Francisco Zapata, Jessica K. Simmons, Esther S. Trueblood, David J. Ortiz, Margo C. Zaval, Katie M. Snead, Steven Jin, Lauren M. Farr, Maureen C. Ryan, Peter D. Senter, Scott C. Jeffrey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (2): 329–339.
https://doi.org/10.1158/1535-7163.MCT-20-0526
Published: 05 February 2021
View article titled, Development of Novel Antibody–Camptothecin Conjugates
Open the PDF for Development of Novel Antibody–Camptothecin Conjugates in another window
Includes: Supplementary data
Journal Articles

AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley S. Chang, Hua Liu, Ian N. Foltz, Esther S. Trueblood, David Meininger, Taruna Arora, Brian Twomey, Steven L. Vonderfecht, Qing Chen, John S. Hill, William C. Fanslow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (7): 1614–1624.
https://doi.org/10.1158/1535-7163.MCT-14-1078
Published: 06 July 2015
View article titled, AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Open the PDF for AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma in another window
Includes: Supplementary data